What to Watch When Johnson & Johnson Reports Tomorrow
Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Johnson & Johnson (NYSE: JNJ | JNJ Price Prediction) is scheduled to report its most recent quarterly results before the markets open on Tuesday. The consensus estimates are calling for $2.43 in earnings per share (EPS) and $20.29 billion in revenue. The second quarter of last year reportedly had $2.10 in EPS and $20.83 billion in revenue.
In the first quarter, consumer worldwide operational sales were driven by over-the-counter products (including Tylenol analgesics, digestive health products and international anti-smoking aids) and Neutrogena beauty products, primarily offset by lower sales of baby care products. Overall consumer sales decreased 2.4% to $3.32 billion year over year.
Worldwide Medical Devices operational sales were driven by the growth of electrophysiology products in the Interventional Solutions business, Acuvue contact lenses in the Vision business, biosurgicals in the Advanced Surgery business and wound closure products in the General Surgery business. At that time, Medical Devices sales decreased 4.6% to $6.46 billion.
Finally, pharmaceutical worldwide operational sales were driven by a number of biologics and biosimilars including Stelara, Imbruvica, Darzalex, Tremfya, Erleada, Remicade and Zytiga to name a few. First-quarter pharmaceuticals sales increased 4.1% to $10.24 billion.
[nativounit]
Excluding Monday’s move, Johnson & Johnson had underperformed the broad markets, with its stock down 4% year to date. In the past 52 weeks, the stock was up closer to 6%.
A few analysts weighed in on the firm ahead of the report:
- Credit Suisse has an Outperform rating and a $156 price target.
- Barclays has a Hold rating with a $140 price target.
- Goldman Sachs has a Buy rating.
- Wells Fargo’s Outperform rating comes with a $157 price target.
- BMO Capital Markets has an Outperform rating and a $157 target.
Shares of Johnson & Johnson traded up 0.5% at $135.01 on Monday, in a 52-week range of $121.00 to $148.99. The consensus price target is $149.17.
[recirclink id=560284]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
